GlassScriptPhysician profile
Ronald S Kent
NPI 1417061250
$1,365.59
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $151 · 2021: $229 · 2022: $278.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $639.41 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $219.71 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $187.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.47 | 2020-2022 | |
| Shire North American Group INC | $114.56 | 2019 | |
| Neos Therapeutics, LP | $45.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.